C Lewden

Summary

Country: France

Publications

  1. doi request reprint All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration
    Charlotte Lewden
    INSERM, U897, ISPED, Université Bordeaux Segalen, Bordeaux, France
    Int J Epidemiol 41:433-45. 2012
  2. doi request reprint CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa
    Charlotte Lewden
    INSERM, U897, Bordeaux, France
    J Acquir Immune Defic Syndr 59:213-9. 2012
  3. pmc Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation
    C Lewden
    INSERM U593, ISPED, Bordeaux, France
    Epidemiol Infect 134:1345-52. 2006
  4. doi request reprint Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic)
    Charlotte Lewden
    INSERM, U897, Bordeaux, France
    J Acquir Immune Defic Syndr 48:590-8. 2008
  5. ncbi request reprint HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population
    Charlotte Lewden
    INSERM, U593, Bordeaux, France
    J Acquir Immune Defic Syndr 46:72-7. 2007
  6. ncbi request reprint An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patients
    Charlotte Lewden
    INSERM U593 exU330, Bordeaux, France
    HIV Clin Trials 5:224-31. 2004
  7. doi request reprint Comparison of early CD4 T-cell count in HIV-1 seroconverters in Côte d'Ivoire and France: the ANRS PRIMO-CI and SEROCO cohorts
    Charlotte Lewden
    INSERM, U897, Bordeaux, France
    J Acquir Immune Defic Syndr 53:260-5. 2010
  8. doi request reprint How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates
    E Lanoy
    INSERM, U720, Paris, France
    HIV Med 10:236-45. 2009
  9. doi request reprint Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data
    Camelia Protopopescu
    INSERM, U912 SE4S, 13006 Marseille, France
    J Antimicrob Chemother 64:599-606. 2009
  10. ncbi request reprint Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohort
    Gaelle Encrenaz
    INSERM, U897, CIC EC7, Bordeaux, F 33076 France
    Curr HIV Res 8:212-7. 2010

Detail Information

Publications29

  1. doi request reprint All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration
    Charlotte Lewden
    INSERM, U897, ISPED, Université Bordeaux Segalen, Bordeaux, France
    Int J Epidemiol 41:433-45. 2012
    ..Using data from a large European collaborative study, we aimed to identify the circumstances in which treated HIV-infected individuals will experience similar mortality rates to those of the general population...
  2. doi request reprint CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa
    Charlotte Lewden
    INSERM, U897, Bordeaux, France
    J Acquir Immune Defic Syndr 59:213-9. 2012
    ..CD4-specific rates of mortality in sub-Saharan African adults with high CD4 counts have rarely been estimated. This estimation is useful to the when to start antiretroviral treatment (ART) debate...
  3. pmc Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation
    C Lewden
    INSERM U593, ISPED, Bordeaux, France
    Epidemiol Infect 134:1345-52. 2006
    ....
  4. doi request reprint Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic)
    Charlotte Lewden
    INSERM, U897, Bordeaux, France
    J Acquir Immune Defic Syndr 48:590-8. 2008
    ..The multicenter national Mortalité 2005 survey aimed at describing the distribution of causes of death among HIV-infected adults in France in 2005 and its changes as compared with 2000...
  5. ncbi request reprint HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population
    Charlotte Lewden
    INSERM, U593, Bordeaux, France
    J Acquir Immune Defic Syndr 46:72-7. 2007
    ..To compare mortality rates in combination antiretroviral therapy (cART)-treated HIV-infected adults with mortality in the general population according to the level of CD4 cell count reached and the duration of exposure to cART...
  6. ncbi request reprint An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patients
    Charlotte Lewden
    INSERM U593 exU330, Bordeaux, France
    HIV Clin Trials 5:224-31. 2004
    ..To describe information bias due to missing data for hepatitis C (HCV) status in the analysis of factors associated with mortality in HIV-infected patients...
  7. doi request reprint Comparison of early CD4 T-cell count in HIV-1 seroconverters in Côte d'Ivoire and France: the ANRS PRIMO-CI and SEROCO cohorts
    Charlotte Lewden
    INSERM, U897, Bordeaux, France
    J Acquir Immune Defic Syndr 53:260-5. 2010
    ..We compared CD4+ decline among untreated HIV-1-infected seroconverters living in Côte d'Ivoire (CI) and in France...
  8. doi request reprint How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates
    E Lanoy
    INSERM, U720, Paris, France
    HIV Med 10:236-45. 2009
    ....
  9. doi request reprint Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data
    Camelia Protopopescu
    INSERM, U912 SE4S, 13006 Marseille, France
    J Antimicrob Chemother 64:599-606. 2009
    ..The aim of this study was to identify factors associated with non-adherence over a 10 year follow-up of the APROCO-COPILOTE cohort during the maintenance phase of highly active antiretroviral therapy (HAART)...
  10. ncbi request reprint Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohort
    Gaelle Encrenaz
    INSERM, U897, CIC EC7, Bordeaux, F 33076 France
    Curr HIV Res 8:212-7. 2010
    ..Tobacco smoking is a major modifiable risk factor of these emergent conditions and almost half of these patients are regular smokers in resource-rich countries...
  11. ncbi request reprint [Causes of death among HIV infected adults in French Guyana and the French West Indies in the era of highly active antiretroviral therapy (HAART)]
    C Lewden
    INSERM U593 exU330, 146, rue Leo Saignat, 33076 Bordeaux Cedex, France
    Med Mal Infect 34:286-92. 2004
    ..The survey "Mortality 2000" had for aim to describe the distribution of causes of death in HIV-infected adults in France...
  12. ncbi request reprint [Epidemiology of discordant virologic and immunologic responses in HIV-1 infected patients]
    R Thiebaut
    INSERM E0338 et INSERM U593, ISPED, Universite Bordeaux 2, Bordeaux, France
    Med Mal Infect 35:S31-2. 2005
  13. ncbi request reprint Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohort
    Charlotte Lewden
    INSERM U330, Bordeaux, France
    J Infect Dis 186:710-4. 2002
    ..Thus, social context plus clinical and biologic data, including the 4-month response to treatment, must be considered in treatment of HIV-infected patients...
  14. ncbi request reprint Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population
    C Lewden
    INSERM U330, Bordeaux, France
    J Acquir Immune Defic Syndr 26:480-2. 2001
    ..2-3.5) and mortality remained 5.1 times higher (95% CI = 1.0-14.9) than in the general population. Failure of treatment, long-term adverse effects, or less favorable socio-demographic status could explain these trends...
  15. pmc Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults
    Fideline Collin
    Inserm U 897, Universite Victor Segalen Bordeaux 2, 146, rue Leo Saignat, Case 11, 33076 Bordeaux Cedex, France
    AIDS 23:1021-4. 2009
    ..6-fold (95% CI = 1.6-8.1) higher in those with hepatitis C virus (HCV) coinfection. Specific monitoring of HCV/HIV-coinfected patients and active promotion of alcohol cessation should be recommended for the prevention of bone fractures...
  16. doi request reprint High frequency of poor locomotor performance in HIV-infected patients
    Laura Richert
    INSERM U, Université Bordeaux Segalen, France
    AIDS 25:797-805. 2011
    ..To provide up-to-date assessments of locomotor function in HIV-infected patients and to identify potential determinants of impaired function...
  17. doi request reprint Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19)
    Mojgan Hessamfar-Bonarek
    INSERM, U897, Bordeaux, France
    Int J Epidemiol 39:135-46. 2010
    ..Little is known about the causes of death in human immunodeficiency virus (HIV)-infected women in the era of combination antiretroviral therapy (ART)...
  18. ncbi request reprint Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy
    Fabrice Bonnet
    Service de Medecine Interne et Maladies Infectieuses, Hôpital Saint André, Bordeaux, France
    Cancer 101:317-24. 2004
    ....
  19. doi request reprint Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort
    Marc Arthur Loko
    INSERM, U593, Bordeaux, France
    Am J Gastroenterol 103:1973-80. 2008
    ..Although an increasing number of noninvasive fibrosis markers are available in HCV-monoinfected patients, data on the performance of these tests in HIV-HCV-coinfected patients are lacking...
  20. ncbi request reprint Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France
    Fabrice Bonnet
    Service de Medecine Interne et Maladies Infectieuses, Hôpital Saint André, Bordeaux, France
    Scand J Infect Dis 37:482-7. 2005
    ....
  21. ncbi request reprint Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey
    Fabrice Bonnet
    Institut National de la Sante et de la Recherche Medicale INSERM, U593, Bordeaux, France
    Clin Infect Dis 48:633-9. 2009
    ....
  22. ncbi request reprint Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS
    Charlotte Lewden
    INSERM U593 exU330, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Int J Epidemiol 34:121-30. 2005
    ..The Mortality 2000 study examined the causes of death in HIV-infected adults at a national level in France in the year 2000...
  23. pmc Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies
    Simon Wandel
    Institute of Social and Preventive Medicine ISPM, University of Bern, Finkenhubelweg 11, CH 3012 Bern, Switzerland
    Sex Transm Infect 84:i31-i36. 2008
    ..Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death...
  24. ncbi request reprint Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study
    Maria Patrizia Carrieri
    INSERM U379, Marseille, France
    Antivir Ther 8:585-94. 2003
    ....
  25. ncbi request reprint Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol
    Dominique Salmon-Ceron
    Internal Medicine Department, Cochin Hospital, Paris, France
    J Hepatol 42:799-805. 2005
    ..We analyzed the characteristics of HIV infected patients who died from liver disease, focusing on hepatitis virus co-infection...
  26. ncbi request reprint [Causes of death in HIV-infected French drug users, 1995-2000]
    Charlotte Lewden
    INSERM U330, 146, rue Leo Saignat, 33076 Bordeaux Cedex
    Ann Med Interne (Paris) 153:2S4-10. 2002
    ..Among IV drug users, improvement in vital prognosis requires to improve management of HCV infection and to take into account socio-economic conditions and other addictive behaviours like alcohol consumption and smoking...
  27. doi request reprint Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity
    Francois Raffi
    AIDS 22:435-6. 2008
  28. ncbi request reprint Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients
    Vincent Le Moing
    Service des Maladies Infectieuses et Tropicales, Hopital Bichat Claude Bernard, Paris, France
    Clin Infect Dis 34:239-47. 2002
    ..89; P=.58). Patients experiencing intolerance should be reassured that changing therapy will probably not be harmful. Multidisciplinary efforts should concentrate on ways to avoid discontinuation of treatment for adherence reasons...
  29. ncbi request reprint The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice
    Virginie Villes
    INSERM U379, Marseilles, France
    Antivir Ther 12:1067-74. 2007
    ..This is especially true for those studies that also consider the possible confounding influence of patient's adherence to treatment...